• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by PDS Biotechnology Corporation

    6/11/25 12:15:09 AM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PDSB alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: June 10, 2025 4:00 P.M.
    Form: S-3
    CIK: 0001472091
    Company Name: PDS Biotechnology Corp
    File Number: 333-287588
    Get the next $PDSB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PDSB

    DatePrice TargetRatingAnalyst
    11/1/2022$10.00Buy
    B. Riley Securities
    8/12/2021$20.00 → $15.00Buy
    HC Wainwright & Co.
    6/28/2021$25.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PDSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on PDS Biotechnology with a new price target

      B. Riley Securities initiated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $10.00

      11/1/22 6:20:52 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on PDS Biotechnology with a new price target

      HC Wainwright & Co. reiterated coverage of PDS Biotechnology with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      8/12/21 11:00:21 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on PDS Biotechnology with a new price target

      Cantor Fitzgerald initiated coverage of PDS Biotechnology with a rating of Overweight and set a new price target of $25.00

      6/28/21 7:38:35 AM ET
      $PDSB
      Biotechnology: Pharmaceutical Preparations
      Health Care